


| Eisai Announces New Investigational Data from Study 211 Evaluating the Starting Dose of LENVIMA® (lenvatinib) in Differentiated Thyroid Cancer at ESMO Asia 2020 |
|
"These investigational data reiterate that the approved dosing of LENVIMA delivers a clinically significant benefit and consistent safety profile for patients with RAI-refractory DTC," said Dr. Takashi Owa, Vice President, Chief Medicine Creation Officer and Chief Discovery Officer, Oncology Business Group at Eisai.
Posted: 2020-11-21 00:19:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.